All In MedTech

Device Trial Radar · NCT02748018

Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home

Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 959 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

959

Actual

Start

May 25, 2017

Primary completion

Nov 1, 2023

Study completion Nov 1, 2023

Sponsor

Lead sponsor
Medtronic MiniMed, Inc.Public (MDT)
Sponsor type
Industry
First posted
Apr 22, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 2 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A diverse population of patients with type 1 diabetes will be studied. The study population will have a large range for duration of diabetes and glycemic control, as measured by glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior diabetes regimen, including using Multiple Daily Injections (MDI), Continuous Subcutaneous Insulin Infusion (CSII) or Sensor-Augmented Pump therapy (SAP)

Conditions

  • Type 1 Diabetes

Interventions

  • 670G and 770G Insulin PumpDevice

    Medtronic 670G and 770G Hybrid Closed Loop Systems

  • Subject's Current Diabetes TherapyDevice

    Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CSII Cohort: Baseline A1C > 8%: Change in A1C (∆A1C)Time frame: Baseline and end of 6-month study period
  2. CSII Cohort: Baseline A1C ≤ 8%: Time in Hypoglycemic RangeTime frame: 6 months study period
  3. MDI Cohort: Baseline A1C > 8%: Change of A1C (∆A1C)Time frame: Baseline and end of 6-month study period

3 more outcomes with a free account

Locations

36 sites in 9 countries. Site status is shown where the registry gives one.

  • Scripps Health System

    La Jolla, California

  • Stanford University

    Palo Alto, California

  • Center of Excellence in Diabetes & Endocrinology

    Sacramento, California

33 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.